Novel BTK Inhibitors: Effects on Adaptive and Innate Immunity in Multiple Sclerosis
Virtual CME/CE Symposium in Conjunction with the Consortium of Multiple Sclerosis Centers
Recent scientific data on disease modifying therapies have shown positive results on penetrating immune cells linked to neuroinflammation in the brain and spinal cord to reduce relapse rates and disability progression in patients with multiple sclerosis (MS). As research continues on the development of this novel brain-penetrant BTK inhibitor with the potential to transform MS treatment, healthcare providers should remain current with the latest data on the science, safety, and long-term efficacy to improve the management and quality of life in their patients.
7:00 pm – 7:10 pm: Why We Need New Approaches to Treating MS – Fred D. Lublin, MD
7:10 pm – 7:30 pm: The Science of BTK Inhibitors: Adaptive and Innate Immunity – Benjamin M. Greenberg, MD, MHS
7:30 pm – 7:50 pm: A Clinical Trial Review and Analysis on the Safety and Efficacy of Novel BTK Inhibitors – Mark S. Freedman, MD
7:50 pm – 8:30 pm: Faculty Panel Discussion: Treatment Strategies for the Application of BTK-Inhibitor Therapeutics to Optimize MS Patient Outcomes– Fred D. Lublin & Faculty
- Understand BTK inhibitor science as a therapeutic target to reduce neuroinflammation and damage to the CNS in patients with MS
- Analyze ongoing clinical trials for the efficacy and safety of novel BTK inhibitors to improve the management of patients with relapsing and progressive forms of MS
- Discuss treatment strategies for the application of newer disease-modifying therapeutics to optimize outcomes in patients with MS
Fred D. Lublin, MD (Course Chair)
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York
Mark S. Freedman, MD
Professor of Medicine
University of Ottawa
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Benjamin M. Greenberg, MD, MHS
Vice Chair of Translational Research
Department of Neurology and Neurotherapeutics
Director, Neuroimmunology Programs
UT Southwestern Medical Center
Children’s Medical Center
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this live material for a maximum of 1.50 AMA PRA Category 1 CreditTM. AcademicCME designates this live material for a maximum of 1.50 CNE contact hours (Provider number P0491). AcademicCME designates this continuing education activity for 1.50 CPE contact hours (0.15 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-20-005-L04-P).
Clinicians should claim only credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CME/CE inquiries or special needs, please contact [email protected] or 610-687-3300.
This activity has been supported by an independent educational grant from Sanofi Genzyme
Provided by AcademicCME
To tune into this virtual event on Thursday, June 25th, please visit: http://virtual.